Popular terms

Immune Disease topics
Immune Disease
Autoimmune
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Immune Disorder
Transplant
Autoimmune Disorders
Type 1 Diabetes
Autoimmune Disorder
Proliferative Disorder
Signs And Symptoms
Proliferative
Antagonist
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Disease patents



      

This page is updated frequently with new Immune Disease-related patent applications.




Date/App# patent app List of recent Immune Disease-related patents
06/23/16
20160176980 
 T-cell redirecting bispecific antibodies for treatment of disease patent thumbnailnew patent T-cell redirecting bispecific antibodies for treatment of disease
The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.

06/23/16
20160176968 
 T-cell redirecting bispecific antibodies for treatment of disease patent thumbnailnew patent T-cell redirecting bispecific antibodies for treatment of disease
The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.

06/23/16
20160176965 
 Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease patent thumbnailnew patent Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
Cytotoxic anti-lag-3 monoclonal antibodies or fragments thereof causing depletion of lag-3+ activated t cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences..

06/23/16
20160176875 
 Spirocyclic ebi2 modulators patent thumbnailnew patent Spirocyclic ebi2 modulators
Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, ebi2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease..

06/23/16
20160176849 
 N-cyanomethylamides as inhibitors of janus kinase patent thumbnailnew patent N-cyanomethylamides as inhibitors of janus kinase
The present invention relates to compounds of general formula (1) that are inhibitors of janus kinase (jak), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound of the invention inhibits jak1 and/or jak2 and/or jak3 sub families.

06/23/16
20160176848 
 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them patent thumbnailnew patent Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .

06/23/16
20160175412 
 Prevention of type 1 diabetes by treg vaccination with an insulin mimetope patent thumbnailnew patent Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
The invention involves methods and products for inducing treg cells for immune suppression in connection with autoimmune disease and transplant rejection.. .

06/23/16
20160175354 
 Therapeutic ozone agent and treatment patent thumbnailnew patent Therapeutic ozone agent and treatment
The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to hypoxic conditions, autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, and cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide and significantly raise systemic oxygen partial pressure to increase the delivery of oxygen to all tissue, systemically, to enable the reversal of hypoxic conditions of the human and animal body and the consequences of those hypoxic conditions, thereby treating or preventing the disease in a patient.. .

06/23/16
20160175353 
 Therapeutic ozone agent and treatment patent thumbnailnew patent Therapeutic ozone agent and treatment
The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide, thereby treating or preventing the disease in a patient.. .

06/23/16
20160175292 
 Antioxidants having aromatic structures reacting with superoxide patent thumbnailnew patent Antioxidants having aromatic structures reacting with superoxide
Disclosed is a method of treating diseases which are: reactive oxygen species mediated, ischemic or reperfusion-related, or t-cell mediated, including autoimmune diseases. The method is administering a therapeutically effective amount of a formulation wherein the active ingredient includes non-phenolic aromatic structures that are electron deficient and are capable of converting the superoxide radical to o2; and/or of converting superoxide radical to oxygen and hydrogen peroxide, or pharmaceutically acceptable salts of said structures.

06/23/16
20160175272 
new patent

Compositions and methods for treatment of inflammation


The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response.

06/16/16
20160168266 

Medicament comprising anti-phospholipase d4 antibody


The present application provides the medicaments comprising the antibodies binding to phospholipase d4 (pld4) as well as a method using said medicaments for detecting and suppressing activated b cells. The present application is further directed to therapy of auto-immune diseases and allergosis, resulting from the active-repressing function.
Sbi Biotech Co., Ltd.


06/16/16
20160168254 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160168248 

Regulatory t cell mediator proteins and uses thereof


In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.

06/16/16
20160168149 

Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


06/16/16
20160168083 

Therapeutic compounds


Or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula i, processes for preparing compounds of formula i, intermediates useful for preparing compounds of formula i and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula i..

06/16/16
20160166708 

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer


Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.


06/16/16
20160166692 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166691 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166690 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166664 

Compositions and methods for induction of antigen-specific tolerance


The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect.
Northwestern University


06/16/16
20160166636 

Modified peptides and their use for treating chronic inflammatory diseases


The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.. .
Centre National De La Recherche Scientifique


06/16/16
20160166611 

Method of preparing injection solution


A method of preparing an injection solution includes: (1) storing a mixture of a blood sample and a divalent cation chelating agent at a temperature between 2 and 12 degrees celsius for a period of from 3 hours to 72 hours so as to have the mixture with two or more separate layers, wherein a liquid in one of the separate layers contains small somatic stem cells such as sb cells; (2) collecting the liquid from the mixture; and (3) after collecting the liquid from the mixture, mixing the liquid with a solution free from ca2+ into the injection solution. The injection solution can be used for an autoimmune disease, such as ankylosing spondylitis, rheumatoid arthritis, or grover's disease..
Stembios Technologies, Inc.


06/09/16
20160160220 

Methods and compositions for treating autoimmune disorders by targeting kv1.3 ion channels with functionalized lipid-derived nanovesicles


Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout sirna, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of t cells by selectively targeting memory t cells with the nanoparticles, which deliver their sirna cargo into the cytosol of the tm cell thus reducing ion channel expression and decreasing ca2+ influx.. .
North Carolina Agricultural And Technical State University


06/09/16
20160160218 

Use of aptamers in therapy and/or diagnosis of autoimmune diseases


The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
Max-delbrueck-centrum Fuer Molekulare Medizin


06/09/16
20160159918 

Methods for diagnosing and treating immune disease


Provided are methods and assays relating to the treatment of an immune disease or disorder by administering an inhibitor that binds slamf7. Also provided are methods and assays related to the diagnosis of an immune disease or disorder by measuring expression level of slamf7 in a biological sample obtained from a subject..
The General Hospital Corporation


06/09/16
20160159802 

18f-labelled folates


The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie


06/09/16
20160159775 

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv


06/09/16
20160158366 

Clathrin therapeutic for autoimmune diseases


The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating an autoimmune disease, condition, or disorder in vivo or in vitro..

06/09/16
20160158352 

Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans


The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic


06/09/16
20160158318 

Methods for treating scleroderma by administering a soluble ctla4 molecule


The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a ctla4 molecule that block endogenous b7 molecules from binding their ligands.. .
Bristol-myers Squibb Company


06/09/16
20160158218 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


06/02/16
20160152951 

Regulatory b cells (tbregs) and their use


Regulatory b cells (tbreg) are disclosed herein. These regulatory b cells express cd25 (cd25+) a pan b cell marker such as b220 (b220+), and also express cd19 (cd19+).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


06/02/16
20160152706 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/02/16
20160152704 

Cadherin 15 agonists


Cdh15 has been identified as a receptor for a peptide which has an inhibitory effect of the migration of t cells. Agonists of this receptor have applications in the treatment and/or prophylaxis of conditions associated with the migration of t-cells, including t cell auto-reactivity, t cell mediated chronic inflammatory disease and autoimmune disease.
The University Of Birmingham


06/02/16
20160152699 

Pan-elr+ cxc chemokine antibodies


Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company


06/02/16
20160152691 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/02/16
20160152599 

Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them


Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .



Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2993

6022

0 - 1 - 115